Axonmedical Ltd - Period Ending 2023-03-31

Axonmedical Ltd - Period Ending 2023-03-31


Axonmedical Ltd 13047920 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is regulation of healthcare, education, cultural and other social services Digita Accounts Production Advanced 6.30.9574.0 true 13047920 2022-04-01 2023-03-31 13047920 2023-03-31 13047920 bus:OrdinaryShareClass1 2023-03-31 13047920 bus:OrdinaryShareClass2 2023-03-31 13047920 core:CurrentFinancialInstruments 2023-03-31 13047920 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 13047920 core:FurnitureFittingsToolsEquipment 2023-03-31 13047920 bus:SmallEntities 2022-04-01 2023-03-31 13047920 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 13047920 bus:FullAccounts 2022-04-01 2023-03-31 13047920 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 13047920 bus:RegisteredOffice 2022-04-01 2023-03-31 13047920 bus:Director1 2022-04-01 2023-03-31 13047920 bus:Director3 2022-04-01 2023-03-31 13047920 bus:Director4 2022-04-01 2023-03-31 13047920 bus:Director5 2022-04-01 2023-03-31 13047920 bus:Director6 2022-04-01 2023-03-31 13047920 bus:Director7 2022-04-01 2023-03-31 13047920 bus:OrdinaryShareClass1 2022-04-01 2023-03-31 13047920 bus:OrdinaryShareClass2 2022-04-01 2023-03-31 13047920 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 13047920 core:FurnitureFittingsToolsEquipment 2022-04-01 2023-03-31 13047920 core:OfficeEquipment 2022-04-01 2023-03-31 13047920 countries:England 2022-04-01 2023-03-31 13047920 2022-03-31 13047920 core:FurnitureFittingsToolsEquipment 2022-03-31 13047920 2020-11-27 2022-03-31 13047920 2022-03-31 13047920 bus:OrdinaryShareClass1 2022-03-31 13047920 bus:OrdinaryShareClass2 2022-03-31 13047920 core:CurrentFinancialInstruments 2022-03-31 13047920 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-31 13047920 core:FurnitureFittingsToolsEquipment 2022-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13047920

Axonmedical Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2023

 

Axonmedical Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 6

 

Axonmedical Ltd

Company Information

Directors

Mr Mehta

Mr Raja

Mr Patel

Mr Cornell

Mr Clyde

Mr Wong

Registered office

4 Arkwright Road
Sanderstead
Surrey
CR2 0LD

Accountants

Mr Piyush Patel
Chartered Certified Accountant
4 Arkwright Road
Sanderstead
Surrey
CR2 0LD

 

Axonmedical Ltd

(Registration number: 13047920)
Balance Sheet as at 31 March 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

36,099

7,699

Current assets

 

Debtors

5

839,959

103,656

Cash at bank and in hand

 

18,384

38,135

 

858,343

141,791

Creditors: Amounts falling due within one year

6

(2,898,667)

(1,174,393)

Net current liabilities

 

(2,040,324)

(1,032,602)

Net liabilities

 

(2,004,225)

(1,024,903)

Capital and reserves

 

Called up share capital

7

8,900

8,750

Retained earnings

(2,013,125)

(1,033,653)

Shareholders' deficit

 

(2,004,225)

(1,024,903)

For the financial year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 28 March 2024 and signed on its behalf by:
 

.........................................
Mr Clyde
Director

 

Axonmedical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
4 Arkwright Road
Sanderstead
Surrey
CR2 0LD

These financial statements were authorised for issue by the Board on 28 March 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

25% straight line

 

Axonmedical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 6 (2022 - 4).

 

Axonmedical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 April 2022

10,265

10,265

Additions

41,288

41,288

At 31 March 2023

51,553

51,553

Depreciation

At 1 April 2022

2,566

2,566

Charge for the year

12,888

12,888

At 31 March 2023

15,454

15,454

Carrying amount

At 31 March 2023

36,099

36,099

At 31 March 2022

7,699

7,699

5

Debtors

Current

2023
£

2022
£

Trade debtors

792,401

-

Prepayments

-

28,058

Other debtors

47,558

75,598

 

839,959

103,656

6

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Due within one year

Trade creditors

245,408

50,508

Taxation and social security

5,468

8,300

Accruals and deferred income

1,572,830

4,449

Other creditors

1,074,961

1,111,136

2,898,667

1,174,393

 

Axonmedical Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2023

7

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary class A of £0.0001 each

100

0.0100

100

0.0100

Ordinary class B of £0.0001 each

88,999,900

8,899.9900

87,499,900

8,749.9900

 

89,000,000

8,900

87,500,000

8,750